Management of pancreatic exocrine insufficiency: Australasian Pancreatic Club recommendations

James Toouli, Andrew V Biankin, Mark R Oliver, Callum B Pearce, Jeremy S Wilson and Nicholas H Wray

Pancreatic exocrine insufficiency (PEI) can occur as a consequence of numerous diseases, including pancreatic cancer, chronic pancreatitis, cystic fibrosis and/or gastrointestinal surgery (particularly pancreatectomy). Although local and international guidelines have been developed for diagnosis and management of these individual disease states, none have focused specifically on diagnosis and management of PEI across all disease states.

The recommendations presented here were developed by the Australasian Pancreatic Club (Box 1) from evidence sourced from Medline, EMBASE and the Cochrane library. Each of the findings and recommendations were categorised according to the available level of evidence (Box 2). The level of evidence is indicated in brackets after each recommendation. Where evidence could not be found, the opinion of the group (denoted as Level 5 evidence) was used to provide guidance. We hope that, where evidence is lacking, these recommendations will serve as an impetus for future research.

1 Development of the recommendations
These recommendations were developed on the initiative of a group of senior members of the Australasian Pancreatic Club. It was done on the realisation that emerging data supported the use of pancreatic enzyme replacement therapy in a manner that had previously not been used, and that patients eligible for this therapy may not have been receiving it in an effective manner. The clinicians met on two occasions, firstly to define the outline of the document, set tasks and develop a mechanism for agreeing on a consensus statement that would make up the recommendations. A decision was made to use the Sackett system for classifying the quality of evidence derived from a wide search of the literature. As the project evolved, communication between members of the group occurred electronically so that consensus was reached. At the second meeting, the recommendations were discussed, and unanimous agreement was reached on each of them. Sheryl Perkin (a medical writer for Grey Healthcare) was engaged to act as an assistant to source relevant publications. These were reviewed by the panel members and summarised in an all-inclusive document. Sheryl also acted as a ghost writer for the original document. The document was then summarised into a manuscript submitted to the Journal.

ABSTRACT

- Pancreatic exocrine insufficiency (PEI) occurs when the amounts of enzymes secreted into the duodenum in response to a meal are insufficient to maintain normal digestive processes.
- The main clinical consequence of PEI is fat malabsorption, resulting in steatorrhea.
- Pancreatic exocrine function is commonly assessed by conducting a 3-day faecal fat test and by measuring levels of faecal elastase-1 and serum trypsinogen.
- Pancreatic enzyme replacement therapy is the mainstay of treatment for PEI.
- In adults, the initial recommended dose of pancreatic enzymes is 25 000 units of lipase per meal, titrating up to a maximum of 80 000 units of lipase per meal.
- In infants and children, the initial recommended dose of pancreatic enzymes is 500 units of lipase per gram of dietary fat; the maximum daily dose should not exceed 10 000 units of lipase per kilogram of bodyweight.
- Oral pancreatic enzymes should be taken with meals to ensure adequate mixing with the chyme.
- Adjunct therapy with acid-suppressing agents may be useful in patients who continue to experience symptoms of PEI despite high-dose enzyme therapy.
- A dietitian experienced in treating PEI should be involved in patient management.
- Dietary fat restriction is not recommended for patients with PEI.
- Patients with PEI should be encouraged to consume small, frequent meals and to abstain from alcohol.
- Medium-chain triglycerides do not provide any clear nutritional advantage over long-chain triglycerides, but can be trialled in patients who fail to gain or to maintain adequate bodyweight in order to increase energy intake.

- Reduced capacity of the pancreas to synthesise enzymes due to loss of or injury to the pancreatic parenchyma;
- Reduced stimulation of enzyme production due to postprandial asynchrony; and
- Impaired delivery of enzymes to the duodenum due to obstruction of the pancreatic duct.

Because of the high reserve capacity of the pancreas and compensatory mechanisms that partly substitute for the loss of pancreatic enzymes, clinical symptoms of PEI do not usually manifest until duodenal lipase levels fall below 5%–10% of normal postprandial levels.
The main clinical consequence of PEI is fat malabsorption and malabsorption, resulting in steatorrhoea. Steatorrhoea is characterised by frothy, foul-smelling and buoyant stools, due to their high fat content. Other symptoms may also include abdominal pain, flatulence and weight loss in adults, or lack of weight gain in children. If left untreated, fat malabsorption may lead to low circulating levels of micronutrients, fat-soluble vitamins and lipoproteins, which have been related to high morbidity because of increased risk of malnutrition-related complications and cardiovascular events.8,9

Diagnosis of pancreatic exocrine insufficiency
Pancreatic exocrine function is difficult to assess because the organ and its secretions are relatively inaccessible. However, it is important to be able to differentiate between pancreatic and non-pancreatic causes of malabsorption or malabsorption and to assess the efficacy of treatment. Pancreatic exocrine function can be tested either directly or indirectly. Direct tests involve collecting pancreatic secretions via duodenal intubation while the pancreas is stimulated with exogenous hormones or intestinal nutrients. Although direct tests are the most sensitive and specific methods for assessing pancreatic exocrine function, their cost and invasive nature limit their routine use in clinical practice.

Indirect tests are less expensive and easier to administer, but are less sensitive and less specific. The 3-day faecal fat test is considered the gold standard for diagnosing and quantifying steatorrhoea, although it does not distinguish between pancreatic and non-pancreatic causes. However, the tedious nature of this test, for both patients and laboratory technicians, makes it an unpopular choice. Of the remaining indirect function tests, faecal elastase-1 and serum trypsinogen tests are most commonly used. A faecal elastase level less than 200 μg/g stool indicates mild PEI, and a level of 100 μg/g stool indicates severe PEI. Serum trypsinogen levels below 20 ng/mL are reasonably specific for PEI in patients over 7 years of age.

In clinical practice, the diagnosis of PEI is usually based on an assessment of the patient’s clinical state, a self-report of bowel movements and weight loss in adults, or failure to thrive in children. Pancreatic enzyme replacement therapy (PERT) can be trialled, and symptom improvement would support a diagnosis of PEI.

Pancreatic enzyme replacement therapy
The primary treatment goal for PEI is to eliminate malabsorption and malabsorption and maintain adequate nutrition. A treatment algorithm is proposed in Box 3. PERT is the mainstay of treatment for PEI. The objective is to deliver sufficient enzymatic activity into the duodenal lumen simultaneously with the meal in order to restore nutrient digestion and aid absorption.

Modern preparations contain pancreatic extract encapsulated in microtablets or mini-microspheres with pH-sensitive enteric coating. The enzymes mix intragastrically with the chyme while being protected from acid degradation by the enteric coating. The enzymes are then emptied from the stomach simultaneously with the chyme. The higher pH in the duodenum dissolves the enteric coating, releasing the enzymes at the appropriate site for digestion and absorption.

The relationship between dose of pancreatic enzymes required and the presence of malabsorption and malabsorption is not linear. Therefore, patients should start on the lowest recommended dose of pancreatic enzymes, which should then be increased and...
titrated to the lowest effective dose (Level 5, Box 4). Initially, PERT was thought to be free of major side effects, but there is an increasing recognition of fibrosing colonopathy and its association with very high doses of oral pancreatic enzymes in patients with cystic fibrosis.\textsuperscript{13-15} For this reason, maximum dose recommendations have been made (Box 4).

Timing related to meals can influence the effectiveness of pancreatic enzymes. If taken before the meal, enzymes may be emptied from the stomach before the meal is emptied. If enzymes are taken after the meal, some of the meal may be emptied before the enzymes. In both cases, digestion may be incomplete. Enzymes should be taken with the meal to ensure adequate mixing with the chyme (Level 2b).\textsuperscript{16}

**Adjuvant therapy**

PERT reduces maldigestion due to PEI and improves the nutritional status of patients. But, in spite of adequate enzyme doses, patients may continue to experience symptoms (in particular, steatorrhoea). This may contribute to malnutrition and weight loss.\textsuperscript{17}

Orally administered pancreatic enzymes can be inactivated by gastric acid.\textsuperscript{18} In theory, drug therapy that reduces gastric acid may improve the effectiveness of PERT. Acid-suppressing agents may be useful for patients who continue to experience symptoms of PEI despite high-dose enzyme therapy (Level 1b).\textsuperscript{19-21}

**Dietary management of pancreatic exocrine insufficiency**

The involvement of a dietitian to oversee dietary management is recommended (Level 5). The role of the dietitian is to assess the nutritional adequacy of the patient’s diet. Dietary advice can then be specifically tailored to improve energy and protein intake and to ensure that the diet is nutritionally adequate in micronutrients.

Weight loss in adults or lack of weight gain in children is common in PEI because of fat malabsorption and the patient’s fear of eating (due to exacerbation of symptoms such as abdominal pain and flatulence). Ensuring adequate growth in children and preventing weight loss in adults is paramount. Historically, dietary fat intake has been restricted in patients with PEI to minimise fat malabsorption and reduce steatorrhoea. However, low-fat diets are lower in total energy content, and restricting fat intake also reduces intake of fat-soluble vitamins, which are already malabsorbed in people with PEI. Today, fat restriction is no longer recommended (Level 5). Normal and high-fat diets have been successfully used in combination with adequate PERT.\textsuperscript{22,23} In children with cystic fibrosis, titration of meal fat content with PERT has evolved (Box 4). As no similar recommendations have been formulated for adults, adult patients need to be educated about how to estimate fat content in meals.

The use of medium-chain triglycerides in the dietary management of PEI is controversial. The potential benefit of medium-chain over long-chain triglycerides is their higher energy value. Few human studies have evaluated the therapeutic efficacy of medium-chain triglycerides in clinical practice, and the results do not suggest any clear nutritional advantage over the usual long-chain triglycerides when pancreatic enzymes are used.\textsuperscript{24-26} Medium-chain triglycerides are poorly tolerated in many patients and can induce side effects such as abdominal pain, nausea and diarrhoea. They may be trialled in patients whose symptoms persist despite enzyme therapy, or when weight gain is very difficult (Level 5).

Food intake may be better distributed across six or more smaller meals throughout the day rather than three large meals. Large meals may not be appetising to a patient with symptomatic PEI, and small meals are often better tolerated (Level 5). The mixing of chyme with pancreatic enzymes is considered more efficient when smaller meals are consumed. This regimen may improve the energy, protein and micronutrient content of the diet, and therefore facilitate weight gain and nutritional improvements.

With any PEI, alcohol abstinence is crucial (Level 3a), as alcohol inhibits gastric lipase secretion, and therefore contributes to fat malabsorption. With time, alcohol consumption can cause more severe and rapid deterioration of pancreatic function.\textsuperscript{27}

**Recommendations in specific disease states**

**Acute pancreatitis in adults**

Acute pancreatitis is an inflammatory disease most commonly caused by gallstones or alcohol abuse\textsuperscript{28} and is associated with significant morbidity and mortality.\textsuperscript{3} While there is no evidence to support the use of PERT during the initial stages of acute pancreatitis (Level 1b),\textsuperscript{29} the data do support the fact that some patients have pancreatic exocrine dysfunction for a period of time after acute pancreatitis. Therefore, patients should be monitored for PEI for at least 6–18 months and treated with oral

### 4 Recommended doses of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency

<table>
<thead>
<tr>
<th>Age group</th>
<th>Initial recommended dose</th>
<th>Maximum recommended dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults (≥ 18 years)</td>
<td>25 000–40 000 units lipase per meal\textsuperscript{8,10}\textsuperscript{*}</td>
<td>75 000–80 000 units lipase per meal\textsuperscript{8,10}</td>
</tr>
<tr>
<td>Children (4–17 years)</td>
<td>500–4000 units lipase per gram of dietary fat\textsuperscript{11} OR 500 units lipase per kilogram of bodyweight per meal\textsuperscript{12}</td>
<td>10 000 units lipase per kg bodyweight per day\textsuperscript{12}</td>
</tr>
<tr>
<td>Children (6 months to 3 years)</td>
<td>500–4000 units lipase per gram of dietary fat\textsuperscript{11} OR 1000 units lipase per kilogram of bodyweight per meal\textsuperscript{12}</td>
<td>10 000 units lipase per kilogram of bodyweight per day\textsuperscript{12}</td>
</tr>
<tr>
<td>Infants (&lt;6 months)</td>
<td>500–1000 units lipase per gram of dietary fat\textsuperscript{11} OR 2000–4000 units lipase per breastfeed or per 120 mL of infant formula\textsuperscript{12}</td>
<td>10 000 units lipase per kilogram of bodyweight per day\textsuperscript{12}</td>
</tr>
</tbody>
</table>

* Enzyme doses should be halved for snacks.
pancreatic enzymes as indicated (Level 2b). As the length of time for recovery of exocrine function appears to depend on the severity of the episode, it may be prudent to supplement patients recovering from an acute necrotising attack with oral pancreatic enzymes and then evaluate exocrine function later in the recovery period (Level 5).

**Chronic pancreatitis in adults**

Chronic pancreatitis is characterised by progressive and irreversible damage to both the exocrine and endocrine components of the pancreas. Alcohol is considered the primary cause, accounting for 60%–70% of all cases. People with alcoholic pancreatitis generally develop PEI within 5–6 years of disease onset. Dietary counselling, coupled with PERT, in patients with chronic pancreatitis not only improves the symptoms of PEI (Level 3a), but can also significantly improve patients’ quality of life (Level 4).

The role of PERT in reducing pain in patients with chronic pancreatitis remains unclear. The American Gastroenterological Association recommends a trial of high-dose pancreatic enzymes coupled with acid suppression therapy before proceeding with continuous use of narcotics or invasive treatment.

**Childhood pancreatitis**

Pancreatitis in children often has a different aetiology and natural history than in adults. There is no evidence for the use of PERT for treatment of acute pancreatitis in children (Level 5). Supplemental enzymes should be used in patients with chronic pancreatitis and documented PEI (Level 5). In patients with painful chronic pancreatitis, PERT may be trialled for pain relief even in the absence of documented PEI (Level 1b).

**Cystic fibrosis**

Cystic fibrosis is a common and lethal genetic disorder that is primarily diagnosed at birth through newborn screening. About 85% of cystic fibrosis patients have pancreatic insufficiency by early childhood. Prolonged, untreated PEI is associated with a poorer prognosis in the long term. Good nutritional management of patients with cystic fibrosis can prevent growth failure and chronic malnutrition. PERT is indicated for those with documented fat malabsorption or PEI. Branded enzyme preparations should be used to ensure high quality and efficacy (Level 2a).

**Bowel surgery**

Bowel surgery involves procedures to remove a diseased part of the large or small intestine. Patients can develop PEI after bowel resection, particularly those who have undergone extensive small bowel surgeries (Level 2a). Theoretically, PERT could be prescribed with gastric acid suppression therapy to enable gastric digestion of nutrients and increase the delivery of digestive products to the small bowel (Level 5).

**Gastrectomy**

Gastrectomy is performed most commonly to treat cancer, bleeding gastric ulcers, polyps and perforations of the stomach wall. Most patients who have undergone partial or total gastrectomy develop PEI, although the causes and underlying mechanisms remain unclear. These patients can benefit from PERT after surgery (Level 2a). Adequate and appropriate enzyme substitution may reduce maldigestion and contribute to improvement in postgastrectomy nutritional status.

**Pancreatectomy**

Pancreatectomy is a treatment option for both benign and malignant diseases of the pancreas. Different pancreatic resections are associated with varying risk of developing PEI. All patients who have undergone pancreatic surgery should be screened for PEI (Level 3a). PEI should be suspected in all patients who have had major pancreatic resection. Although difficult to diagnose in these patients, it is important to try to establish the presence of PEI, as long-term oral PERT can significantly improve the quality of life in these patients (Level 4).

**Unresectable pancreatic cancer**

About 90% of patients with pancreatic cancer have weight loss at the time of diagnosis. Weight loss may be exacerbated by maldigestion and malabsorption, as a result of destroyed pancreatic tissue reducing the availability of pancreatic enzymes. Results in PEI with associated steatorrhoea can be used to treat PEI in patients with unresectable pancreatic cancer to help maintain weight and improve overall quality of life (Level 2a).

**Coeliac disease**

PEI is common in patients with untreated coeliac disease, but is reversible in those who have a good clinical response to gluten withdrawal. Patients with persisting symptoms after gluten withdrawal should have their pancreatic exocrine function assessed. Those found to have PEI should be treated with PERT (Level 2b). Supplementation with pancreatic enzymes may also benefit infants with coeliac disease in the period immediately after diagnosis, irrespective of pancreatic function (Level 1b).

**Diabetes mellitus**

As the exocrine and endocrine portions of the pancreas are linked anatomically and physiologically, any disease affecting one part has the potential to affect the other part. PEI is frequently associated with both type 1 and type 2 diabetes mellitus. In about 60% of patients, the PEI can cause characteristic steatorrhoea, and treatment with PERT may be indicated (Level 4).

**Human immunodeficiency virus**

Fat malabsorption is a frequent problem in patients with HIV infection. Steatorrhoea may be due to PEI in about 30% of cases (Level 3b). Treatment with PERT can reduce faecal fat loss and relieve the symptoms of steatorrhoea in HIV-infected patients with fat malabsorption (Level 4).

**Irritable bowel syndrome**

Irritable bowel syndrome is a common condition, characterised by abdominal pain, bloating and abnormal bowel habit. PEI may occur in patients with diarrhoea-predominant irritable bowel syndrome (Level 2b). Treatment with PERT may reduce diarrhoea and abdominal pain (Level 3b).
Conclusion
Through the development of these recommendations it has become apparent that there is a lack of good quality clinical evidence for many areas in the management of PEI. In such instances, recommendations are based primarily on clinical experience rather than clinical data. PERT remains the mainstay treatment for PEI. However, it is difficult to draw conclusions from a number of clinical trials because of significant differences in study design. There is no standardised method for assessing pancreatic exocrine function, and thus no defined criteria for diagnosing PEI. Furthermore, over the past 50 years, PERT has evolved, and numerous different formulations have been developed, evaluated and marketed during that time. In addition to these methodological issues, PEI has diverse aetiologies and patients with PEI are a heterogeneous population. Clearly, further research is needed to optimise patient management. A copy of the full recommendations is available at the Australasian Pancreatic Club website (http://www.pancreas.org.au).

Acknowledgements
We gratefully acknowledge the assistance of Sheryl Perkin in researching the literature and in medical writing of the recommendations and manuscript. The activities of the Australasian Pancreatic Club’s committee were supported by an unrestricted educational grant from Solvay Pharmaceuticals.

Competing interests
The Australasian Pancreatic Club has received an unrestricted educational grant from Solvay Pharmaceuticals to support the formation of a committee to develop evidence-based recommendations. The South Western Sydney Clinical School, University of New South Wales, has received an unrestricted educational grant from Solvay Pharmaceuticals to support time spent in preparing the manuscript. James Toouli, Andrew Blankin, Mark Oliver, Callum Pearce and Nicholas Wray have received payment from Solvay Pharmaceuticals to attend meetings relating to preparation of the recommendations.

Author details
James Toouli, MB BS, FRACS, PhD, Professor1
Andrew V Blankin, MB BS, PhD, FRACS, Professor and Head of Pancreatic Cancer Research Group2
Mark R Oliver, MB BS, MD, FRACP, Associate Professor and Deputy Director3
Callum B Pearce, MB ChB, MD, FRACP, Associate Professor4
Jeremy S Wilson, MD, FRACP, FRCP, Clinical Associate Dean5
Nicholas H Wray, MND, BAppSc(ExSportSc), APD, Dietitian6
1 Department of Surgery, Flinders Medical Centre, Adelaide, SA.
2 Garvan Institute of Medical Research, Sydney, NSW.
3 Department of Gastroenterology and Clinical Nutrition, Royal Children’s Hospital, Melbourne, VIC.
4 School of Medicine and Pharmacology, Fremantle Hospital Unit, University of Western Australia, Perth, WA.
5 South Western Sydney Clinical School, University of New South Wales, Liverpool Hospital, Sydney, NSW.
6 Flinders Private Hospital, Adelaide, SA.
Correspondence: jim.toouli@flinders.edu.au

References
18 Zentner-Munro PL, Fine DR, Batten JC, Northfield TC. Effect of cimetidine on enzyme inactivation, bile acid precipitation, and lipid solubilisation in pancreatic steatorrhoea due to cystic fibrosis. Gut 1985; 26: 892-901.

(Received 6 Apr 2010, accepted 20 Jun 2010)